Investigating the Levels of Soluble Extracellular Domain of HER2 Protein in the Sera of Meningioma Patients

Shabnam ABTAHI¹, Sareh HAKIMRABET¹, Mahyar MALEKZADEH¹, Amir Reza DEGHANIAN², Abbas GHADERI¹,³

¹Shiraz University of Medical Sciences, Shiraz Institute for Cancer Research, Shiraz, Iran
²Shiraz University of Medical Sciences, Department of Pathology, Shiraz, Iran
³Shiraz University of Medical Sciences, Department of Immunology, Shiraz, Iran

ABSTRACT

AIM: Meningiomas are the most frequently diagnosed primary central nervous system neoplasms. Considering slightly higher incidence of meningiomas in breast cancer patients and breast cancer in meningioma patients, it can be assumed that both tumors share similar risk factors. HER2 gene amplification and/or over-expression have been found in several human cancers, but it has been most widely studied in breast carcinomas. Bearing in mind the association of breast cancer and meningioma, the present study aimed to investigate the levels of the soluble extracellular domain of HER2 protein in meningioma cases and control group. Besides, in the present research, its associations with pathological features and prognostic indicators of meningioma were examined.

MATERIAL and METHODS: In the present study, 68 meningioma patients along with 20 healthy age-sex matched individuals, as controls, were selected. Levels of HER2 in the sera were measured by a quantitative enzyme-linked immunosorbent assay (ELISA).

RESULTS: The observations showed that Serum HER2 levels in meningioma patients were significantly lower than normal controls. However, outlier quantities were mostly observed in the cases. Furthermore, in meningiomas with higher histological grade (grade II, III), statistically significant elevated serum levels of HER2 were observed compared to patients with low-grade meningiomas (grade I).

CONCLUSION: Serum HER2 levels were a poor biomarker for determination of pathological and prognostic characteristics of meningiomas and coupling serum HER2 levels with immunohistochemistry examination of HER2 in meningioma tissue samples would be helpful in future studies.

KEYWORDS: Cancer biomarker, HER2, Meningioma, Prognosis


INTRODUCTION

Meningiomas are the most frequently diagnosed primary central nervous system tumors in adults, comprising approximately one-third of all cases (26). The incidence of meningioma increases progressively with age and these tumors are more common in women (16). A number of factors have been studied for a possible relationship to the development of meningiomas, including: ionizing radiation, genetic predispositions, hormonal factors, breast cancer, and obesity (18). Considering slightly higher incidence of meningiomas in breast cancer patients and breast cancer in meningioma patients, it can be assumed that both tumors share similar risk factors, such as hormonal risk factors and/or underlying genetic predispositions (6,26).
The HER2 (also known as ERBB2) gene is a proto-oncogene located at 17q12, and encodes a 185-kd transmembrane glycoprotein which belongs to the family of tyrosine kinase growth factor receptors (1). The four members of HER protein family mediate major cellular functions including proliferation, differentiation, motility, and survival (4). HER2 gene amplification and/or overexpression have been found in some human cancers, such as gastric, esophageal, endometrial, ovarian, and rarely in lung and bladder cancers (10), but it has been most widely studied in breast carcinomas (9).

In 1993, reports from different studies demonstrated the expression of the HER2 protein in meningiomas (19,21). Considering the association of breast cancer and meningioma, and probable similarities in their risk factors, Chozik et al. (1996) hypothesized that altered expression of the HER2 protein was one of the shared pathogenesis pathway, occurring in both breast carcinomas and meningiomas (5). They observed a difference in HER2 expression of typical and atypical meningiomas (5). Further studies demonstrated HER2 gene amplification with Fluorescence In Situ Hybridization (FISH) in meningiomas (13). Besides, reports that showed higher rates of recurrence in HER2-positive meningiomas in comparison to HER2-negative ones (2,13,23), suggested a potential role of HER2 protein expression in the determination of meningioma prognosis. In addition, Wang et al. (2010) demonstrated that over-expression of HER2 resulted in meningiomas with increased cell invasion, migration, and proliferation, whereas down-regulation of HER2 protein expression inhibited the neoplastic cells’ motility and proliferation, which led to an increase in apoptosis and arrest cell cycle at the G0/G1-phase (24). In addition, higher expression of HER2 in higher grades of meningioma (grade II, III) in comparison to low-grade tumors (grade I) has been reported (13,15). On the other hand, there are studies that report no association between HER2 expression and meningioma features (14).

Almost all of the studies on HER2 in meningioma were performed on tumor samples. However, the extracellular domain of HER2 protein can be shed from the surface of neoplastic cells into the circulation and measurement of soluble extracellular domain of HER2 protein in the sera (sHER2) can possibly offer a less invasive method of determining HER2 expression in meningiomas rather than a biopsy. Considering the potential role of HER2 in the determination of meningioma prognosis, the present study aimed to investigate the HER2 serum levels in meningioma cases and to examine its associations with pathological features and prognostic indicators.

**MATERIAL and METHODS**

In the present study, 68 meningioma patients along with 20 healthy sex-age matched individuals, as controls, were involved. The mean age of diagnosis in patients was 53.5±13.0 years (range= 24-86 years), and 69.1% (n=47) of them were females. Most pathological samples were reported to be grade I meningiomas (60.3%; n=41). Further pathological features of the meningiomas are presented in Table I.

A statistically significant difference between sHER2 levels of cases and control group was observed. Interestingly, the sHER2 levels were significantly lower in the cases compared to control group (Figure 1A; 34.49 vs. 39.65 pg/ml; p=0.008). Although median of HER2 serum levels were higher in healthy individuals, outlier quantities were mostly observed in the case group (Figure 1A). However, no significant shared characteristics were observed in this group of meningioma. Furthermore, HER2 serum levels were higher in the patients with grade II or III meningioma compared to grade I patients (Figure 1B; 39.18 vs. 33.78 pg/ml; p=0.016). No other association was observed between serum levels of HER2 and pathological features and histological variants of meningioma.

**DISCUSSION**

To our best knowledge, there have been no reports on the levels of serum HER2 in meningioma patients. In the present study, we tried to investigate HER2 serum levels and associate these
levels with pathological features and prognostic indicators of meningioma. The observations showed that HER2 serum levels in meningioma patients were significantly lower than the control group. However, outlier quantities were mostly observed in the cases. Furthermore, in meningiomas with higher histological grade (grade II, III), a statistically significant elevated serum levels of HER2 was observed in comparison to patients with low-grade meningioma (grade I).

To date, almost all the studies had demonstrated HER2 immunoreactivity in meningiomas; however, the reported range differs considerably (2% to 100%) (22). Loussouarn et al. (2006) reported that HER2 protein was over-expressed in about 30% of the meningiomas (13). In this study, we observed that serum levels of HER2 were significantly higher in control group. There are several explanations for the discrepancy we observed. We believe that profile of tissue expression of HER2 in meningioma may not necessarily match with its serum levels. Since in the present research, the expression of HER2 on the neoplastic cells of meningioma was not studied, the observations in the serum might be the result of HER2 expression in meningiomas expressing poles apart levels of HER2 protein. This also could be the reason that we observed outlier levels of serum HER2 only in the meningioma patients. Furthermore, the patients were pathologically diagnosed with

Table I: Pathological Characteristics of Meningioma Samples and Their Respective Serum HER2 Levels

<table>
<thead>
<tr>
<th>Pathological Features</th>
<th>Valid Percent (n)</th>
<th>HER2 (pg/ml)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathological Grade</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>77.8% (42)</td>
<td>33.78</td>
<td>0.03*2</td>
</tr>
<tr>
<td>II</td>
<td>13.0% (7)</td>
<td>37.77</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>9.3% (5)</td>
<td>39.18</td>
<td></td>
</tr>
<tr>
<td><strong>Histological Variant</strong></td>
<td></td>
<td></td>
<td>0.262</td>
</tr>
<tr>
<td>Microcystic</td>
<td>11.8% (2)</td>
<td>-3</td>
<td></td>
</tr>
<tr>
<td>Meningothelial</td>
<td>5.9% (1)</td>
<td>-4</td>
<td></td>
</tr>
<tr>
<td>Fibroblastic</td>
<td>11.8% (2)</td>
<td>-4</td>
<td></td>
</tr>
<tr>
<td>Angiomatous</td>
<td>17.6% (3)</td>
<td>-4</td>
<td></td>
</tr>
<tr>
<td>Secretory</td>
<td>5.9% (1)</td>
<td>-4</td>
<td></td>
</tr>
<tr>
<td>Rhabdoid</td>
<td>5.9% (1)</td>
<td>-4</td>
<td></td>
</tr>
<tr>
<td>Papillary</td>
<td>23.5% (4)</td>
<td>-4</td>
<td></td>
</tr>
<tr>
<td>Anaplastic</td>
<td>17.6% (3)</td>
<td>-4</td>
<td></td>
</tr>
<tr>
<td><strong>Brain Invasion</strong></td>
<td></td>
<td></td>
<td>0.11*3</td>
</tr>
<tr>
<td>Yes</td>
<td>10.3% (7)</td>
<td>40.58</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>89.7% (61)</td>
<td>34.25</td>
<td></td>
</tr>
</tbody>
</table>

1HER2 serum levels are presented as median; 2Kruskal-Wallis test; 3Mann-Whitney U test; 4Values were not calculated in median because of low number of cases.
meningioma, which means serum samples were collected at least 2 months after surgery. Therefore, one can expect that the levels of HER2 on the fresh tissue will be different to that of serum samples.

Another explanation for this discrepancy could be the enzymatic digestion of extracellular domain of HER2 shed in the blood, which has been previously shown in case of breast cancer (author personal observation). Moreover, tumor cells express many potential immunogenic proteins, called tumor-associated antigen (TAAs), which are also found in normal cells at low levels (8). Durand et al. (2008) reported that HER2 expression in meningiomas was higher than in normal meningeal tissue, but was similar in all tumors, regardless of their grade and histological type (7). Higher expression of HER2 in these tumors can activate an immune response against this molecule. The presence of HER2 autoantibodies has been demonstrated in the sera of breast cancer patients (11,20). An additional reason for our observation could be over-expression of HER2 in meningioma patients, which triggers autoantibody production against a HER2 antigen in the serum of meningioma patients, and consequently, inability of the ELISA to detect this antigen.

Up to this point, most studies have been scrutinizing the expression of the HER2 protein in the neoplastic cells of meningioma. Consistent with our observations, Abdelzaher et al. (2011) reported a significant direct correlation between HER2 expression in meningiomas and their proliferation index (2). Wang et al. (2015) observed that when the gene expression of HER2 was down-regulated, the proliferative and invasive ability of the meningioma cells were decreased, and these cells had higher rates of apoptosis (24). Moreover, consistent with our results, some studies reported the higher expression of HER2 on the surface of higher grade meningiomas, although they stated no statistical significance for this association (14,15). On the other hand, there are studies that report no correlation between HER2 expression and histological grade and prognosis of meningiomas (17,25), and a few studies have even shown decreased HER2 expression in higher grade meningiomas (3).

**CONCLUSION**

Levels of serum HER2 are a poor biomarker for determination of pathological and prognostic characteristics of meningiomas. The limitations of this study were the low number of participants and not examining the past medical history of patients more thoroughly. For further clarifying the significance of HER2 serum levels and its association with pathological features, the studies that measure the levels of shER2 coupled with immunohistochemistry examination of HER2 in meningioma tissue samples would be helpful. Examining the presence of neutralizing autoantibodies against shER2 in meningiomas with HER2 over-expression would also help further clarify our observations.

**ACKNOWLEDGEMENT**

This work was supported by a grant from Shiraz University of Medical Sciences (grant number: 93-01-01-7776 ).

**REFERENCES**


